Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA v. Michigan

Executive Summary

Michigan plans to implement its supplemental Rx rebate program Feb. 1 following a stay of the preliminary injunction by the Michigan Court of Appeals Jan. 16. A Lansing state court had granted the Pharmaceutical Research & Manufacturers of America's request for a preliminary injunction on Jan. 7 (1"The Pink Sheet" Jan. 14, p. 24)..

You may also be interested in...



AARP Health Litigation Brief Supports Michigan Supplemental Rebates

AARP's litigation team has filed an amicus brief supporting use of supplemental rebates in the Michigan Medicaid program

Michigan Supplemental Rx Rebate Program Lacks Statutory Authority – Judge

Michigan Medicaid lacks the statutory authority to mandate supplemental rebates for prescription drugs, Lansing circuit court Judge Lawrence Glazer found in granting the Pharmaceutical Research & Manufacturers of America's request for a preliminary injunction against the program

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Latest Headlines
See All
UsernamePublicRestriction

Register

PS039191

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel